Cortexyme (CRTX) Competitors $1.20 +0.03 (+2.56%) As of 06/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, BDTX, TARA, PLX, CABA, CCCC, SGMO, and IVVDShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Black Diamond Therapeutics (BDTX), Protara Therapeutics (TARA), Protalix BioTherapeutics (PLX), Cabaletta Bio (CABA), C4 Therapeutics (CCCC), Sangamo Therapeutics (SGMO), and Invivyd (IVVD). Cortexyme vs. Its Competitors Omnicell HealthStream Veradigm Black Diamond Therapeutics Protara Therapeutics Protalix BioTherapeutics Cabaletta Bio C4 Therapeutics Sangamo Therapeutics Invivyd Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends. Does the MarketBeat Community favor CRTX or OMCL? Omnicell received 354 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 66.75% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote. CompanyUnderperformOutperformCortexymeOutperform Votes15464.44% Underperform Votes8535.56% OmnicellOutperform Votes50866.75% Underperform Votes25333.25% Do analysts rate CRTX or OMCL? Omnicell has a consensus target price of $44.83, indicating a potential upside of 47.53%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omnicell 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has more volatility and risk, CRTX or OMCL? Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CRTX or OMCL? 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by company insiders. Comparatively, 2.5% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, CRTX or OMCL? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.40Omnicell$1.14B1.25$12.53M$0.4666.07 Is CRTX or OMCL more profitable? Omnicell has a net margin of 1.13% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Omnicell 1.13%3.82%2.07% Does the media favor CRTX or OMCL? In the previous week, Omnicell had 5 more articles in the media than Cortexyme. MarketBeat recorded 5 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 0.81 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Overall Sentiment Cortexyme Neutral Omnicell Positive SummaryOmnicell beats Cortexyme on 15 of the 17 factors compared between the two stocks. Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.18M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.4033.3227.1420.06Price / SalesN/A469.84411.98157.10Price / CashN/A168.6838.2534.64Price / Book0.303.457.064.70Net Income-$89.94M-$72.35M$3.23B$247.88M7 Day Performance14.29%6.23%2.85%2.63%1 Month Performance17.65%16.53%9.06%6.36%1 Year Performance52.28%-16.90%31.43%14.05% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.20+2.6%N/A+57.9%$36.18MN/A-0.4055OMCLOmnicell3.1481 of 5 stars$31.68+2.2%$44.83+41.5%+3.4%$1.48B$1.14B117.343,800HSTMHealthStream4.506 of 5 stars$28.22-1.1%$31.50+11.6%-0.4%$861.42M$292.37M43.421,140Positive NewsMDRXVeradigm2.5209 of 5 stars$4.40flat$13.00+195.5%-53.2%$476.37M$1.53B0.008,000Gap UpBDTXBlack Diamond Therapeutics3.4812 of 5 stars$2.48-3.9%$14.60+488.7%-61.1%$141.02M$70M-1.8690TARAProtara Therapeutics2.4871 of 5 stars$3.27-2.1%$20.50+526.9%+20.1%$126.16MN/A-1.1630Analyst RevisionGap UpPLXProtalix BioTherapeutics2.6414 of 5 stars$1.54-2.5%$15.00+874.0%+31.9%$122.60M$59.76M-11.85200Positive NewsCABACabaletta Bio2.9095 of 5 stars$2.37-4.4%$20.33+757.9%-84.2%$120.26MN/A-1.1050Trending NewsAnalyst ForecastAnalyst RevisionGap DownCCCCC4 Therapeutics2.217 of 5 stars$1.68-2.9%$12.00+614.3%-68.7%$119.29M$39.78M-0.99150Positive NewsGap UpSGMOSangamo Therapeutics2.2198 of 5 stars$0.51-3.8%$4.50+782.4%-14.6%$118.92M$63.76M-0.68480Positive NewsIVVDInvivyd3.8205 of 5 stars$0.97-2.1%$5.85+504.2%-46.4%$118.69M$36.69M-0.49100Positive News Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Black Diamond Therapeutics Alternatives Protara Therapeutics Alternatives Protalix BioTherapeutics Alternatives Cabaletta Bio Alternatives C4 Therapeutics Alternatives Sangamo Therapeutics Alternatives Invivyd Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
